Читать книгу Veterinary Surgical Oncology - Группа авторов - Страница 119

The WHO staging system for cutaneous MCT (Table 4.2) has been reported to be prognostic for tumor‐free time and survival time with surgical MCT treatment (Turrel et al. 1988).

The presence of lymph node metastasis (WHO stage II disease) has been shown in multiple studies to be associated with a poorer prognosis compared to stage I disease (Murphy et al. 2006; Hume et al. 2011; Turrel et al. 1988; Krick et al. 2009). The lymph node metastasis classification system (HN0‐HN3) is helpful to be more precise regarding the prognostic significance (Weishaar et al. 2014). Dogs with grade III primary cutaneous MCTs are more likely to have metastatic MCT in regional lymph nodes (Krick et al. 2009). Dogs with lymph nodes affected by metastatic disease that are treated with either surgery or radiation have prolonged survival time compared to untreated lymph node‐positive dogs (Hume et al. 2011; Bae et al. 2020). A different study contradicts this finding for Grade 2 MCTs, showing that positive lymph node status does not adversely affect survival time (Baginski et al. 2014). Dogs with stage IV disease at presentation have a very poor prognosis (Pizzoni et al. 2018).